Therapeutic options in metastatic uveal melanoma

Developments in Ophthalmology

Volumn 49, Issue , 2012, Pages 166-181

  Mariani, Pascale ^a   Servois, Vincent ^a   Piperno Neumann, Sophies ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; MELANOMA; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; UVEA MELANOMA; UVEA TUMOR;

COMBINED MODALITY THERAPY; HUMANS; MELANOMA; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC; UVEAL NEOPLASMS;

EID: 84925965382     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000328333     Document Type: Article

References (62)

1. Singh AD, Topham A: Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110:962-965.
2. Kujala E, Mäkitie T, Kivelä T: Very long-term prognosis of patients with malignant uveal melanoma. Ophthalmology 2003;110:962-965.
3. Desjardins L, Dorval T, Levy C, Cojean I, Schlienger P, Salmon RJ, Validire P, Asselain B: Etude randomisée de chimiothérapie adjuvante par le deticène dans le mélanome choroïdien. Ophtalmologie 1998; 12:168-173.
4. Desjardins L, Levy-Gabriel C, Lumbroso-Lerouic L, Sastre X, Dendale R, Couturier J, Piperno-Neumann S, Dorval T, Mariani P, Salmon R, Plancher C, Asselain B: Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research. J Fr Ophtalmol 2006;29:741-749.
5. Abramson DH, Servodidio CA: Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. Arch Ophthalmol 1997;115:134.
6. Schirrmacher V: T-cell immunity in the induction and maintenance of a tumour dormant state. Semin Cancer Biol 2001;11:285-295.
7. Blom DJ, Schurmans LR, De Waard-Siebinga I, De Volff-Rouendaal D, Keunen JE, Jager MJ: HLA expression in a primary uveal melanoma, its cell line, and four of its metastases. Br J Ophthalmol 1997;81:989-993.
8. Augsburger JJ, Corrêa ZM, Shaikh AH: Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009;148:119-127.
9. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R: Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347: 1222-1225.
10. Onken MD, Worley LA, Ehlers JP, Harbour JW: Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64:7205-7209.
11. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM, Rees RC: Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997;19:22-28.
12. Trolet J, Hupé P, Huon I, Lebigot I, Decraene C, Delattre O, Sastre-Garau X, Saule S, Thiéry JP, Plancher C, Asselain B, Desjardins L, Mariani P, Piperno-Neumann S, Barillot E, Couturier J: Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci 2009;50:2572-2580.
13. Onken MD, Worley LA, Person E, Char DH, Bowcock AM, Harbour JW: Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res 2007;13:2923-2927.
14. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J, Collaborative Ocular Melanoma Study Group: Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No 26. Arch Ophthalmol 2005;123:1639-1643.
15. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE, Spar MD: Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98:383-390.
16. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS: Treatment of uveal melanoma metastatic to the liver: A review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 1995;76: 1665-1670.
17. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S: Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988;260:974-976.
18. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T: Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: Results of a phase II study. Melanoma Res 2005;15:297-304.
19. Vogl T, Eichler K, Zangos S, Herzog C, Hammerstingl R, Balzer J, Gholami A: Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: Local tumor control and survival. J Cancer Res Clin Oncol 2007;133:177-184.
20. Dayani PN, Gould JE, Brown DB, Sharma KV, Linette GP, Harbour JW: Hepatic metastasis from uveal melanoma: Angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol 2009;127:628-632.
21. Keilholz U, Scheibenbogen C, Brado M, Georgi P, Maclachlan D, Brado B, Hunstein W: Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur J Cancer 1994;30A:103-105.
22. Feldman ED, Pingpank JF, Alexander HR Jr: Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004;11:290-297.
23. Van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ: Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol 2008;15: 1891-1898.
24. Van Etten B, de Wilt JH, Brunstein F, Eggermont AM, Verhoef C: Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. Eur J Surg Oncol 2009;35: 539-545.
25. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L: Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997;15:2589-2595.
26. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Piperno-Neumann S, Stupp R, Leyvraz S: Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: Experience in 101 patients. Ann Oncol 2006;17:578-583.
27. Egerer G, Lehnert T, Max R, Naeher H, Keilholz U, Ho AD: Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma. Int J Clin Oncol 2001;6:25-28.
28. Siegel R, Hauschild A, Kettelhack C, Kahler KC, Bembenek A, Schlag PM: Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 2007;33: 627-632.
29. Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB: Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002;87:840-845.
30. Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, Sato T: High-dose immunoembolization: Survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 2009;252:290-298.
31. Kennedy AS, Nutting C, Jakobs T, Cianni R, Notarianni E, Ofer A, Beny A, Dezarn WA: A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009;27:682-690.
32. Zografos L: Tumeurs intraoculaires. Paris, Masson, 2002, pp 212-229.
33. Piperno-Neumann S, Chaaba H, Plancher C, Mariani P, Couturier J, Sastre-Garau X, Servois V, Asselain B, Desjardins L: Retrospective analysis of 470 metastatic uveal melanoma patients managed at Institut Curie (2000 and 2008). Proc ESMO. Ann Oncol 2010;21(suppl 8):viii401-viii407.
34. Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis NE, Schuster R, Siehl JM, Foerster MH, Thiel E, Keilholz U: A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 2006;17:1826.
35. Agarwala SS, Glaspy J, et al: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125-133.
36. Piperno-Neumann S: Therapeutic options in uveal metastatic melanoma patients. European uveal melanoma workshop, Paris, March 2007.
37. Triozzi P, Eng C, Singh AD: Targeted therapy for uveal melanoma. Cancer Treat Rev 2008;34:247-258.
38. Penel N, Delcambre C, Durando X, Clisant S, Hebbar M, Negrier S, Fournier C, Isambert N, Mascarelli F, Mouriaux F: O-Mel-Inib: A Cancéropôle Nord-Ouest multicenter phase II trial of highdose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs 2008;26:561-565.
39. Hofmann UB, Kauczok-Vetter CS, Houben R, Becker JC: Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 2009;15:324-329.
40. Yang H, Jager MJ, Grossniklaus HE: Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 2010;51:2835-2842.
41. Rajpal S, Moore R, Karakousis CP: Survival in metastatic ocular melanoma. Cancer 1983;52:334-336.
42. Seregard S, Kock E: Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand 1995;73:340-344.
43. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB: Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005;23: 8076-8080.
44. Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, et al: Treatment of liver metastases from uveal melanoma by combined surgerychemotherapy. Eur J Surg Oncol 1998;24:127-130.
45. Rivoire M, Kodjikian L, Baldo S, Kaemmerlen P, Négrier S, Grange JD: Treatment of liver metastases from uveal melanoma. Ann Surg Oncol 2005;12: 422-428.
46. Mariani P, Piperno-Neumann S, Servois V, Berry M, Dorval T, Plancher C, Couturier J, Levy-Gabriel C, Lumbroso-Le Rouic L, Desjardins L, Salmon RJ: Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol 2009; 35:1192-1197.
47. Prenikumar A, Marincola F, Taubenberger J, Chow C, Venzon D, Schwartzentruher D: Metastatic melanoma: Correlation of MRI characteristics and histopathology. J Magn Res Imaging 1996;1:190-194.
48. Meli RJ, Ros PR: MR appearance of intra-abdominal metastatic melanoma. Magn Res Imaging 1992;10:7 05-708.
49. Servois V, Mariani P, Malhaire C, Petras S, Piperno-Neumann S, Plancher C, Levy C, Desjardins L, Salmon RJ: Comparison of MRI and FDG-PET for staging of uveal melanoma liver metastases. Eur J Surg Oncol 2010;36:189-194.
50. Nasu K, Kuroki Y, Nawano S, et al: Hepatic metastases: Diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006;239: 122-130.
51. Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, et al: Protracted survival after resection of metastatic uveal melanoma. Cancer 2000;89:1561-1568.
52. Hsueh EC, Essner R, Foshag LJ, Ye X, Wang He-Jing, Morton DL: Prolonged survival after complete resection of metastases from intra-ocular melanoma. Cancer 2004;100:122-129.
53. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al: Screening for metastases from choroidal melanoma: The collaborative ocular melanoma study group report 23. J Clin Oncol 2004;22:2438-2444.
54. Sato T, Babazono A, Shields JA, Shields CL, De Potter P, Mastrangelo MJ: Time to systemic metastases in patients with posterior uveal melanoma. Cancer Invest 1997;15:98-105.
55. Kurli M, Reddy S, Tena L, Pavlick A, Finger P: Whole body PET/CT staging of metastatic choroidal melanoma. Am J Ophthalmol 2005;140:193-199.
56. Francken A, Fulham M, Millward M, Thompson J: Detection of metastatic disease in patients with uveal melanoma using PET. Eur J Surg Oncol 2006;32:780-784.
57. Ghanem N, Altehoefer C, Högerie S, Nitzsche E, Lohrmann C, Schäfer O, Kotter E, Langer M: Detectability of liver metastases in malignant melanoma: Prospective comparison of MRI and PET. Eur J Radiol 2005;54:264-270.
58. Dirisamer A, Halpern BS, Schima W, et al: Dualtime-point FDG-PET/CT for detection of hepatic metastases. Mol Imaging Biol 2008;10:335-340.
59. Lucignani G, Paganeli G, Modorati G, et al: MRI, antibody-guided scintigraphy and glucose metabolism in uveal melanoma. J Comput Assist Tomogr 1992;16:77-83.
60. Strobel K, Bode B, Dummer P, et al: Limited value of 18F-FDG PET/CT and S-100B tumor marker in the detection of liver metastases from uveal melanoma compared to liver metastases of cutaneous melanoma. Eur J Nucl Med Mol Imaging 2009;36:1774-1782.
61. Lindholm P, Leskinen S, Nagren K, et al: Carbon-11-methionine PET imaging of malignant melanoma. J Nucl Med 1995;3:1806-1810.
62. Dimitrakopoulou-Strauss A, Strauss LG, Burger C: Quantitative PET studies in pretreated melanoma patients: A comparison of 6-(18F)fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. J Nucl Med 2001;42: 248-256.